ZYXI Pengajuan SEC - Zynex, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

846475

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zynex, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 20, 2025	EX-99.1	Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles Exhibit 99.1 Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles ENGLEWOOD, Colo., August 18, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, St
August 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Zynex, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I
July 31, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00
July 31, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 31, 2025	EX-99.1	Zynex Reports Second Quarter 2025 Financial Results Exhibit 99.1 Zynex Reports Second Quarter 2025 Financial Results ENGLEWOOD, Colo., July 31, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. M
July 29, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 24, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi
July 24, 2025	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm
July 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Zynex, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 2, 2025	EX-10.2	Form of Indemnification Agreement Exhibit 10.2 FORM OF ZYNEX, INC. INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (“Agreement”), dated as of [DATE] (“Effective Date”), is by and between Zynex, Inc., a Nevada corporation (“Company”) and [NAME OF DIRECTOR/OFFICER] (“Indemnitee”) (collectively, “Parties”). A. Indemnitee is [a director/an officer] of Company/Company expects Indemnitee to join Company as [a director/an office
July 2, 2025	EX-99.1	Zynex Announces Steven Dyson as New CEO Exhibit 99.1 Zynex Announces Steven Dyson as New CEO Englewood, CO – June 30, 2025 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Steven Dyson as Chief Executive Officer. His employment will begin on August 18, 2025. Thomas Sandgaard, F
July 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2025 Zynex, Inc. (Exact N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
July 2, 2025	EX-10.1	Employment Agreement, dated May 23, 2025, between Zynex, Inc. and Steven Dyson Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is effective as of May 23, 2025 (“Effective Date”), between Zynex, Inc., a Nevada corporation headquartered at 9655 Maroon Circle, Englewood, Colorado 80112, USA, (“Company”), and Steven Dyson, PhD (“Executive”) (collectively, “Parties”). A. Company is a duly organized Nevada corporation, with its principal place of business
July 2, 2025	EX-99.1	Tricare Temporary Payment Suspension Update Exhibit 99.1 Tricare Temporary Payment Suspension Update ENGLEWOOD, Colo., July 2, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company received an update from Tricare that the temporary payment suspension will cont
June 24, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
May 15, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
May 14, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
May 14, 2025	EX-99.1	Zynex Submits FDA Application for Its NiCO Laser Pulse Oximeter Exhibit 99.1 Zynex Submits FDA Application for Its NiCO Laser Pulse Oximeter ENGLEWOOD, Colo., May 12, 2025 /PRNewswire/ - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has submitted a 510(k) application to the U.S. Food and
April 29, 2025	EX-99.1	Zynex Reports First Quarter 2025 Financial Results Exhibit 99.1 Zynex Reports First Quarter 2025 Financial Results ENGLEWOOD, Colo., April 29, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. M
April 29, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0
April 29, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
April 25, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Zynex, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwa
April 25, 2025	S-3	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZYNEX, INC. (Exact name of registrant as specified in its charter) Table of Contents Registration No. 333-[ ] SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada 90-0275169 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9655 Maroon Circle Englewood, CO 80112 (800) 495-
March 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934s Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat
March 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
March 27, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
March 27, 2025	EX-16.1	Letter from Marcum LLP to the Securities and Exchange Commission dated March 27, 2025. EX-16.1 2 zyxi-20250327xex16d1.htm EX-16.1 Exhibit 16.1 March 27, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Zynex, Inc. under Item 4.01 of its Form 8-K dated March 27, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of
March 17, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
March 11, 2025	EX-21	Subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF ZYNEX, INC. Name Jurisdiction Zynex Medical, Inc. Colorado Zynex Monitoring Solutions, Inc. Colorado Zynex NeuroDiagnostics, Inc. Colorado Kestrel Labs, Inc. Colorado
March 11, 2025	EX-99.1	Zynex Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Zynex Reports Fourth Quarter and Full Year 2024 Financial Results ENGLEWOOD, Colo., March 11, 2025 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and ful
March 11, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804
March 11, 2025	EX-10.4	Lease Agreement, effective February 16, 2023, between Two Maroon Circle Investors, LLC and Zynex, Inc. Exhibit 10.4 LEASE AGREEMENT BY AND BETWEEN TWO MAROON CIRCLE INVESTORS, LLC, a Delaware limited liability company AS LANDLORD AND ZYNEX, INC., a Nevada corporation AS TENANT DATED FEBRUARY , 2023 TABLE OF CONTENTS 1. DEMISE 2 2. PREMISES 2 3. TERM 4 4. RENT 4 5. UTILITIES AND SERVICES 15 6. LATE CHARGE 19 7. SECURITY DEPOSIT 20 8. POSSESSION; COMPLETION OF THE LANDLORD WORK 20 9. USE OF PREMISES;
March 11, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
March 11, 2025	EX-19.1	Insider Trading Policy, as initially adopted on February 26, 2004 and as amended, from time to time. Exhibit 19.1 ZYNEX INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) provides guidelines to all employees, officers, and affiliates of Zynex, Inc., and its subsidiaries (the “Company”), as well as members of the Company’s Board of Directors (the “Directors”), with respect to transactions in the Company’s securities and codifies the Company’s standards on trading and enabling, or ca
October 24, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 24, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb
October 24, 2024	EX-99.1	Zynex Reports Third Quarter 2024 Financial Results Exhibit 99.1 Zynex Reports Third Quarter 2024 Financial Results ENGLEWOOD, Colo., October 24, 2024 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2
July 25, 2024	EX-99.1	Zynex Reports Second Quarter 2024 Financial Results Q2 2024 Revenue Increased 11% to $49.9 Million Exhibit 99.1 Zynex Reports Second Quarter 2024 Financial Results Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo., July 25, 2024 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational result
July 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 Zynex, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 25, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00
May 16, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
April 30, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
April 30, 2024	EX-99.1	Zynex Reports First Quarter 2024 Financial Results Q1 2024 Revenue Increased 10% to $46.5 Million Exhibit 99.1 Zynex Reports First Quarter 2024 Financial Results Q1 2024 Revenue Increased 10% to $46.5 Million ENGLEWOOD, Colo., April 30, 2024 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational result
April 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0
April 12, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 1, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
March 12, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 ZYNEX,
March 12, 2024	EX-21	Subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF ZYNEX, INC. Name Jurisdiction Zynex Medical, Inc. Colorado Zynex Monitoring Solutions, Inc. Colorado Zynex NeuroDiagnostics, Inc. Colorado Zynex Europe, ApS Denmark Kestrel Labs, Inc. Colorado
March 12, 2024	EX-97	Zynex, Inc. Clawback Policy (incorporated by reference to Exhibit 97 of the Company’s Annual Report on Form 10-K filed on March 12, 2024) ZYNEX, INC. CLAWBACK POLICY EFFECTIVE November 28, 2023 1. Purpose. The purpose of this Zynex Inc. (the “Company”) Clawback Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed to comply with, and shall be interpreted to be c
February 29, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
February 29, 2024	EX-99.1	Zynex Reports Fourth Quarter and Full Year 2023 Financial Results FY 2023 Revenue Increased 17% to $184.3 Million Company Announces Additional $20 Million Stock Repurchase Plan Zynex Reports Fourth Quarter and Full Year 2023 Financial Results FY 2023 Revenue Increased 17% to $184.
November 1, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
November 1, 2023	EX-99.1	Zynex Announces Share Repurchase Program Exhibit 99.1 Zynex Announces Share Repurchase Program ENGLEWOOD, CO – November 1, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to repurchase up to $20.0 million of the Comp
October 31, 2023	EX-99.1	Zynex Announces Review of Strategic Alternatives Exhibit 99.1 Zynex Announces Review of Strategic Alternatives ENGLEWOOD, CO – October 31, 2023 –Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its Board of Directors (the “Board”) has initiated a process to evaluate potential st
October 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Zynex, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 26, 2023	EX-99.1	Zynex Reports Third Quarter 2023 Financial Results Q3 2023 Revenue Increased 20% to $49.9 Million; EPS $0.10 Exhibit 99.1 Zynex Reports Third Quarter 2023 Financial Results Q3 2023 Revenue Increased 20% to $49.9 Million; EPS $0.10 ENGLEWOOD, Colo., October 26, 2023 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has reported its financial and operati
October 26, 2023	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 26, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb
September 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 Zynex, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
September 11, 2023	EX-99.1	Zynex Announces Share Repurchase Program Exhibit 99.1 Zynex Announces Share Repurchase Program Englewood, CO – September 11, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to repurchase $10.0 million of the Company'
July 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Zynex, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Zynex, Inc. (Exact name of registrant as specified in charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E
July 31, 2023	EX-10.1	Amendment to Stock Purchase Agreement by and among Kestrel Labs, Inc., Zynex Monitoring Solutions, Inc. And Selling Shareholders named therein dated as of July 27, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 31, 2023) Exhibit 10.1 AMENDMENT TO STOCK PURCHASE AGREEMENT This Amendment, dated and executed effective as of July 27, 2023 (this "Amendment"), to that certain Stock Purchase Agreement, dated as of December 22, 2021 (the "SPA"), entered into by and among Kestrel Labs, Inc., a Colorado corporation (the "Company"), Jonas Pologe, Theodore Delianides, Kurt Aronow and Kevin Galligan (collectively, the "Selling
July 27, 2023	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00
July 27, 2023	EX-99.1	Zynex Reports Second Quarter 2023 Financial Results Q2 2023 Revenue increased 22% to $45.0 Million; EPS $0.09 Exhibit 99.1 Zynex Reports Second Quarter 2023 Financial Results Q2 2023 Revenue increased 22% to $45.0 Million; EPS $0.09 ENGLEWOOD, Colo., July 27, 2023 /PRNewswire/ - Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has reported its financial
July 12, 2023	EX-99.1	Zynex Reports Preliminary Second Quarter 2023 Results Exhibit 99.1 Zynex Reports Preliminary Second Quarter 2023 Results ENGLEWOOD, CO – July 12, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for second quarter 2023 and reiterated full-year guidance. "Zy
July 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 Zynex, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
June 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 Zynex, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
June 20, 2023	EX-99.1	Zynex Receives FDA Clearance of CM-1600 Monitor for Improved Blood and Fluid Management Exhibit 99.1 Zynex Receives FDA Clearance of CM-1600 Monitor for Improved Blood and Fluid Management Englewood, CO – June 20, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the FDA (Food and Drug Administration) has
June 14, 2023	EX-99.1	Zynex Announces Share Buyback Program Exhibit 99.1 Zynex Announces Share Buyback Program Englewood, CO – June 14, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company's common s
June 14, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
May 24, 2023	EX-99.1	AMENDED AND RESTATED AGREEMENT TO FILE JOINT SCHEDULE 13D Exhibit 99.1 AMENDED AND RESTATED AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of ZYNEX, INC., a Nevada co
May 24, 2023	SC 13D/A	ZYXI / Zynex Inc / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 17) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9655 Maroon Circle Englewood, CO
May 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Zynex, Inc. (Exact N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Zynex, Inc. (Exact N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
May 9, 2023	EX-99.1	Zynex Announces Proposed $50 Million Offering of Convertible Senior Notes Exhibit 99.1 Zynex Announces Proposed $50 Million Offering of Convertible Senior Notes ENGLEWOOD, Colo., May 3, 2023 /PRNewswire/ - Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), today announced its intent to offer, subject to market conditions and other factors, $50 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes") in a private offering (the "Notes Offering") to per
May 9, 2023	EX-99.3	Zynex Announces Proposed Secondary Public Offering of Common Stock Exhibit 99.3 Zynex Announces Proposed Secondary Public Offering of Common Stock ENGLEWOOD, Colo., May 3, 2023 /PRNewswire/ - Zynex, Inc. ("Zynex" or "the Company") (Nasdaq: ZYXI), today announced the commencement of an underwritten public offering of 2,000,000 shares of its common stock by Thomas Sandgaard, its Chief Executive Officer (the "Secondary Offering"). Mr. Sandgaard also intends to grant
May 9, 2023	EX-4.1	Indenture dated as of May 9, 2023, between Zynex, Inc. And U.S. Bank Trust Company, National Association, as trustee, (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 9, 2023) Exhibit 4.1 ZYNEX, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 9, 2023 5.00% Convertible Senior Notes due 2026 TABLE OF CONTENTS Page ARTICLE 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 14 ARTICLE 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01. Designation and Amount 14 Section 2.0
May 9, 2023	EX-4.2	Form of certificate representing the 5.00% Convertible Senior Notes due 2023 (included as Exhibit A to Exhibit 4.1) Exhibit 4.2 EXHIBIT A   [FORM OF FACE OF NOTE]   [INCLUDE FOLLOWING LEGEND IF A GLOBAL NOTE]   [UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME A
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Zynex, Inc. (Exact Na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.S
May 9, 2023	EX-99.2	Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering Exhibit 99.2 Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering ENGLEWOOD, Colo., May 4, 2023 /PRNewswire/ - Zynex, Inc. ("Zynex") (Nasdaq: ZYXI ), announced today the pricing of its previously announced private offering of $52.5 million aggregate principal amount of 5.00% convertible senior notes due 2026 (the "Notes") in a private offering (the "Notes Offering") to persons reas
May 9, 2023	EX-99.4	Zynex Announces Update Regarding Previously Announced Offerings Exhibit 99.4 Zynex Announces Update Regarding Previously Announced Offerings ENGLEWOOD, Colo., May 4, 2023 /PRNewswire/ - Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), today announced that Thomas Sandgaard, its Chief Executive Officer (the "Selling Stockholder"), has determined not to pursue the public offering of 2,000,000 shares of the Company's common stock that was previously announced on May 3, 2023
May 3, 2023	424B7	SUBJECT TO COMPLETION, DATED MAY 3, 2023 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
April 27, 2023	EX-99.1	Zynex Announces 2023 First Quarter Earnings Exhibit 99.1 Zynex Announces 2023 First Quarter Earnings Englewood, CO, April 27, 2023 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights: o
April 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0
April 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Zynex, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
April 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 Zynex, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
April 11, 2023	EX-99.1	Zynex Reports Preliminary First Quarter 2023 Results Exhibit 99.1 Zynex Reports Preliminary First Quarter 2023 Results ENGLEWOOD, CO – April 11, 2023 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for first quarter 2023 and reiterated full year guidance. "We
March 30, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
March 30, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 tm2310595d1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru
March 14, 2023	EX-21	Subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF ZYNEX, INC. Name Jurisdiction Zynex Medical, Inc. Colorado Zynex Monitoring Solutions, Inc. Colorado Zynex NeuroDiagnostics, Inc. Colorado Zynex Europe, ApS Denmark Kestrel Labs, Inc. Colorado
March 14, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 ZYNEX,
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Zynex, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
March 13, 2023	EX-99.1	Zynex Announces 2022 Fourth Quarter and Full Year Earnings Exhibit 99.1 Zynex Announces 2022 Fourth Quarter and Full Year Earnings Englewood, CO, March 13, 2023 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the fourth quarter and full year ended December 31, 2022.
February 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Zynex, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
February 21, 2023	EX-99.1	Zynex Leases New Facility to Accommodate Growth Exhibit 99.1 Zynex Leases New Facility to Accommodate Growth ENGLEWOOD, Colo., February 21, 2023 /PRNewswire/ - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the lease of a new 41,000 square foot facility to accommodate Zynex M
November 1, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Zynex, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
November 1, 2022	EX-99.1	Zynex Announces Additional Share Buyback Program Exhibit 99.1 Zynex Announces Additional Share Buyback Program Englewood, CO – November 1, 2022 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Comp
October 27, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
October 27, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 27, 2022	EX-99.1	Zynex Announces 2022 Third Quarter Earnings Exhibit 99.1 Zynex Announces 2022 Third Quarter Earnings Englewood, CO, October 27, 2022 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlig
July 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
July 28, 2022	EX-99.1	Zynex Announces 2022 Second Quarter Earnings Exhibit 99.1 Zynex Announces 2022 Second Quarter Earnings Englewood, CO, July 28, 2022 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights:
July 28, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 11, 2022	EX-99.1	Zynex Reports Preliminary Second Quarter 2022 Results and Reiterates Full Year Revenue and EBITDA Guidance Exhibit 99.1 Zynex Reports Preliminary Second Quarter 2022 Results and Reiterates Full Year Revenue and EBITDA Guidance ENGLEWOOD, CO ? July 11, 2022 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for secon
July 11, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
June 29, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
June 13, 2022	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
June 13, 2022	EX-99.1	Zynex Announces Change of Auditor Exhibit 99.1 Zynex Announces Change of Auditor Englewood, CO ? June 13, 2022 ? Zynex, Inc. (?Zynex or the ?Company) (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has changed its auditors from Plante & Moran, PLLC (?Plante Moran?) a
June 13, 2022	EX-16.1	Letter from Plante & Moran PLLC Exhibit 16.1 Plante & Moran, PLLC Suite 600 8181 E. Tufts Avenue Denver, CO 80237 Tel: 303.740.9400 Fax: 303.740.9009 plantemoran.com June 13, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read Item 4.01 included in the Form 8-K of Zynex, Inc. filed with the Securities and Exchange Commission regarding its change in auditors. We agree with t
June 9, 2022	EX-99.1	Zynex Announces Additional Share Buyback Program Exhibit 99.1 Zynex Announces Additional Share Buyback Program Englewood, CO ? June 9, 2022 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company'
June 9, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
May 19, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
April 29, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
April 29, 2022	EX-99.1	Zynex Announces 2022 First Quarter Earnings Exhibit 99.1 Zynex Announces 2022 First Quarter Earnings Englewood, CO, April 28, 2022 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the first quarter ended March 31, 2022. Highlights: o Revenue increased
April 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
April 11, 2022	EX-99.1	Zynex Announces Share Buyback Program Exhibit 99.1 Zynex Announces Share Buyback Program ENGLEWOOD, CO ? April 11, 2022 ? Zynex, Inc. (NASDAQ: ZYXI an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation and patient monitoring, today announced that its board of directors approved a program to buy back $10.0 million of the Company's common sto
April 11, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
April 8, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 8, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
April 8, 2022	EX-99.1	Zynex Reports Preliminary First Quarter 2022 Results and Provides Business Update Exhibit 99.1 Zynex Reports Preliminary First Quarter 2022 Results and Provides Business Update ENGLEWOOD, CO ? April 8, 2022 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for first quarter 2022, affirming
April 1, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
March 22, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 22, 2022	EX-4.2	Description of registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.2 to the Company’s Annual Report on Form 10-K filed on March 22, 2022) Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Zynex Inc. (?Zynex? or the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). DESCRIPTION OF COMMON STOCK The authorized capital stock of the Company consists of 100,000,000 shares of
March 22, 2022	EX-21	Subsidiaries of the Company Exhibit 21 ? SUBSIDIARIES OF ZYNEX, INC. ? ? ? ? Name Jurisdiction Zynex Medical, Inc. ? Colorado Zynex Monitoring Solutions, Inc. ? Colorado Zynex NeuroDiagnostics, Inc. ? Colorado Zynex Europe, ApS ? Denmark Pharmazy, Inc ? Colorado Kestrel Labs, Inc. ? Colorado ?
February 28, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
February 28, 2022	EX-99.1	Zynex Announces 2021 Fourth Quarter and Full Year Earnings Exhibit 99.1 Zynex Announces 2021 Fourth Quarter and Full Year Earnings Englewood, CO, February 24, 2022 - Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported financial results for the fourth quarter and full year ended December 31, 20
January 18, 2022	EX-99.1	Zynex Announces Increased Q4 2021 Adjusted EBITDA Estimate and 18% Order Growth Exhibit 99.1 Zynex Announces Increased Q4 2021 Adjusted EBITDA Estimate and 18% Order Growth ENGLEWOOD, CO ? January 18, 2022 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation and patient monitoring, today announced order growth and an increased Adjusted EBITDA estimate
January 18, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
December 30, 2021	EX-10.1	The Loan Agreement and accompanying documents dated December 22, 2021 among Bank of America N.A., Zynex Medical, Inc., and Zynex Monitoring Solutions (incorporated by reference to Exhibit 10.1 of the Company’s Report on Form 8-K filed on December 30, 2021) Exhibit 10.1 loan AGREEMENT This Agreement dated as of December 22, 2021 is among Bank of America, N.A. (the "Bank") and Zynex Medical, Inc. and Zynex Monitoring Solutions, Inc. (collectively, jointly and severally, the "Borrower"). 1. definitions In addition to the terms which are defined elsewhere in this Agreement, the following terms have the meanings indicated for the purposes of this Agreeme
December 30, 2021	8-K	Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 (December 22, 2021) ZYNEX, INC. (Exact name of registrant as specified in charter) Nevada 001-38804 90-0275169 (State or other jurisdiction (Commission (IRS Employer
December 23, 2021	EX-99.1	Zynex Announces Acquisition of Kestrel Labs Expanding Its Product Portfolio in Patient Monitoring EXHIBIT 99.1 Zynex Announces Acquisition of Kestrel Labs Expanding Its Product Portfolio in Patient Monitoring ENGLEWOOD, CO ? December 23, 2021 / PRNewswire/ - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has acquired 100%
December 23, 2021	EX-10.1	Stock Purchase Agreement by and among Kestrel Labs, Inc., Zynex Monitoring Solutions Inc., Zynex, Inc. and Selling Shareholders named herein dated as of December 22, 2021 (incorporated by reference to Exhibit 10.1 of the Company’s Report on Form 8-K filed on December 23, 2021) Exhibit 10.1 STOCK PURCHASE AGREEMENT by and among Kestrel Labs, Inc., Zynex Monitoring Solutions Inc., Zynex, Inc. and the Selling Shareholders named herein dated as of December 22, 2021 TABLE OF CONTENTS ARTICLE I DEFINITIONS 2 ARTICLE II PURCHASE AND SALE 16 Section 2.01 Purchase and Sale. 16 Section 2.02 Purchase Price. 16 Section 2.03 Transactions to be Effected at the Closing. 16 Section 2.0
December 23, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 (December 22, 2021) ZYNEX, INC. (Exact name of registrant as specified in charter) Nevada 001-38804 90-0275169 (State or other jurisdiction (Commission (IRS Employer
November 10, 2021	EX-99.1	Zynex Declares Special Cash Dividend of $0.10 Per Share and 10% Stock Dividend Exhibit 99.1 Zynex Declares Special Cash Dividend of $0.10 Per Share and 10% Stock Dividend ENGLEWOOD, CO ? November 10, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced it has declared a one
November 10, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
November 3, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
November 2, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
November 2, 2021	EX-99.1	Zynex Announces 2021 Third Quarter Earnings Exhibit 99.1 Zynex Announces 2021 Third Quarter Earnings ? 2021 Third Quarter o Revenue increased 74% year over year to $34.8 million o Orders increased 70% o Record net income of $6.1 million; Diluted EPS $0.17 o Adjusted EBITDA $9.3 million ENGLEWOOD, CO ? November 2, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invas
November 2, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
October 13, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 13, 2021	EX-99.1	Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate Exhibit 99.1 Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate ENGLEWOOD, CO ? October 13, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased
July 29, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
July 29, 2021	EX-99.1	Zynex Announces 2021 Second Quarter Earnings Exhibit 99.1 Zynex Announces 2021 Second Quarter Earnings ? 2021 Second Quarter o Revenue increased 61% year over year to $31.0 million o Orders increased 247% o Net income of $2.8 million; Diluted EPS $0.08 o Adjusted EBITDA $4.8 million ENGLEWOOD, CO ? July 29, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive med
July 29, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 15, 2021	EX-99.1	Zynex Announces 247% Order Growth and Increases Q2 Adjusted EBITDA Estimate Exhibit 99.1 Zynex Announces 247% Order Growth and Increases Q2 Adjusted EBITDA Estimate ENGLEWOOD, CO ? July 15, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased Adjust
July 15, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
May 26, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
April 29, 2021	EX-99.1	Zynex Announces 2021 First Quarter Earnings Exhibit 99.1 Zynex Announces 2021 First Quarter Earnings ? 2021 First Quarter o Revenue increased 58% year over year to $24.1 million o Orders increased 140% o Net loss of $0.7 million; GAAP loss per share $0.02 o Adjusted EBITDA loss $0.4 million ENGLEWOOD, CO ? April 29, 2021 ? Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-in
April 29, 2021	10-Q	Quarterly Report - FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
April 29, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
April 12, 2021	EX-99.1	Zynex Announces 140% Year over Year Order Growth in Q1-2021 Exhibit 99.1 Zynex Announces 140% Year over Year Order Growth in Q1-2021 ENGLEWOOD, CO – April 12, 2021 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q1 2021. Thomas Sandgaard, CEO of
April 12, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
April 9, 2021	EX-10.1	Sublease Agreement between Zynex, Inc. and Cognizant Trizetto Software Group, Inc. dated April 8, 2021 (incorporated by reference to Exhibit 10.1 of the Company’s Report on Form 8-K filed on April 9, 2021) Exhibit 10.1 SUBLEASE AGREEMENT This Sublease Agreement (?Sublease?) is dated April 8, 2021, and is between COGNIZANT TRIZETTO SOFTWARE GROUP, INC., a Delaware corporation (?Sublandlord?), and ZYNEX, INC., a Nevada corporation (?Subtenant?). Sublandlord, by its predecessor in interest, The Trizetto Group, Inc., as tenant, and Maroon Englewood LLC, a Delaware limited liability company (?Prime Landl
April 9, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
April 2, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
March 8, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
March 8, 2021	EX-99.1	Zynex Announces Share Buyback Program Exhibit 99.1 Zynex Announces Share Buyback Program ENGLEWOOD, CO – March 8, 2021 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that its board of directors approved a program to buy back $10.0 m
February 25, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
February 25, 2021	EX-21	Subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF ZYNEX, INC. ? ? ? ? ? Name Jurisdiction Zynex Medical, Inc. ? Colorado ? Zynex Monitoring Solutions, Inc. ? Colorado ? Zynex NeuroDiagnostics, Inc. ? Colorado ? Zynex Europe, ApS ? Denmark ? Pharmazy, Inc ? Colorado ? ?
February 25, 2021	10-K	Annual Report - 10-K Table of Contents ? ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 25, 2021	EX-4	Description of registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Zynex Inc. (?Zynex? or the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). DESCRIPTION OF COMMON STOCK The authorized capital stock of the Company consists of 100,000,000 shares of
February 25, 2021	EX-99.1	Zynex Announces 2020 Fourth Quarter and Full Year Earnings Exhibit 99.1 Zynex Announces 2020 Fourth Quarter and Full Year Earnings · 2020 Full Year o Revenue increased 76% year over year to $80.1 million o Orders increased 96% o Net income of $9.1 million; Diluted EPS $0.26 o Adjusted EBITDA $13.7 million o 2020 Revenue and Adjusted EBITDA are the highest in Company history · 2020 Fourth Quarter o Revenue increased 81% year over year to $25.6 million o Or
January 28, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2021 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
January 28, 2021	EX-99.1	Zynex Appoints Anna Lucsok as Chief Operating Officer of Zynex Medical Exhibit 99.1 Zynex Appoints Anna Lucsok as Chief Operating Officer of Zynex Medical ENGLEWOOD, Colo., (PR Newswire, January 28, 2021) - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has pr
January 28, 2021	EX-10.1	Employment Agreement effective January 27, 2021, entered into between Zynex Medical, Inc. and Anna Lucsok Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into effective January 27, 2021 (the “Effective Date”), by Anna Lucsok (“Executive”) and Zynex Medical (the “Company”). RECITALS A. Company desires to hire Executive as Chief Operating Officer and to compensate Executive for Executive’s services to the Company; and B. Executive wishes to be employed by the Co
January 12, 2021	EX-99.1	Zynex Announces 117% Year over Year Order Growth and Increases Adjusted EBITDA Estimate Exhibit 99.1 Zynex Announces 117% Year over Year Order Growth and Increases Adjusted EBITDA Estimate ENGLEWOOD, CO – January 12, 2021 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q4 2
January 12, 2021	8-K	Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
December 7, 2020	8-K	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2020 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
December 2, 2020	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 16) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO
December 2, 2020	EX-99.1	AMENDED AND RESTATED AGREEMENT TO FILE JOINT SCHEDULE 13D Exhibit 99.1 AMENDED AND RESTATED AGREEMENT TO FILE JOINT SCHEDULE 13D Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of ZYNEX, INC., a Nevada co
November 10, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 27, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb
October 27, 2020	EX-99.1	Zynex Announces Third Quarter 2020 Earnings Exhibit 99.1 Zynex Announces Third Quarter 2020 Earnings · Revenue increased 69% year over year to $20.0 million · Orders increased 96% · Net income of $1.3 million; Diluted EPS $0.04 · Adjusted EBITDA $2.4 million ENGLEWOOD, CO – October 27, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain
October 27, 2020	8-K	Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 23, 2020	EX-99.1	Zynex Appoints Neil Friery as President and Chief Operating Officer of Monitoring Solutions Division Exhibit 99.1 Zynex Appoints Neil Friery as President and Chief Operating Officer of Monitoring Solutions Division ENGLEWOOD, Colo., (PR Newswire, October 23, 2020) - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics
October 23, 2020	EX-10.1	Employment Agreement, dated October 22, 2020, between Zynex, Inc. and Neil Friery (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed October 23, 2020). Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into effective October 5th, 2020 (the “Effective Date”), by Neil Friery (“Executive”) and Zynex, Inc. (the “Company”). RECITALS A. Company desires to hire Executive as President and Chief Operating Officer and to compensate Executive for Executive’s services to the Company; and B. Executive wishes to be emplo
October 23, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 13, 2020	8-K	Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 13, 2020	EX-99.1	Zynex Announces 96% Year over Year Order Growth Exhibit 99.1 Zynex Announces 96% Year over Year Order Growth ENGLEWOOD, CO – October 12, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q3 2020. Thomas Sandgaard, CEO of Zynex said
October 6, 2020	EX-99.1	Zynex Continued Growth Leads to a New Manufacturing and Warehouse Facility Exhibit 99.1 Zynex Continued Growth Leads to a New Manufacturing and Warehouse Facility ENGLEWOOD, CO – October 6, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the lease of a new 50,488 squ
October 6, 2020	8-K	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
October 6, 2020	EX-10.1	Lease Agreement, effective September 30, 2020, between GIG CW Compark, LLC and Zynex, Inc. (incorporated by reference to Exhibit 10.1 of the Company’s Report on Form 8-K filed on October 6, 2020). Exhibit 10.1 LEASE AGREEMENT between GIG CW COMPARK, LLC (“Landlord”) and ZYNEX, INC. (“Tenant”) Table of Contents Page 1. CERTAIN DEFINED TERMS 1 2. GRANT OF LEASE 2 3. RENT; SECURITY DEPOSIT 3 4. USE 5 5. TAXES 6 6. LANDLORD’S REPAIRS AND OBLIGATIONS 7 7. TENANT’S REPAIRS AND OBLIGATIONS 8 8. ALTERATIONS 9 9. SIGNAGE 10 10. INSPECTION AND RIGHT OF ENTRY 10 11. UTILITIES 10 12. ASSIGNMENT AND SUB
September 10, 2020	EX-99.1	Zynex Reaches 400 Salesperson Milestone Ahead of Schedule Exhibit 99.1 Zynex Reaches 400 Salesperson Milestone Ahead of Schedule ENGLEWOOD, CO – September 10, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced reaching four hundred sales reps in the U.S
September 10, 2020	8-K	Regulation FD Disclosure - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
September 9, 2020	EX-99.1	Zynex reports 83% Order Growth for July and August Exhibit 99.1 Zynex reports 83% Order Growth for July and August ENGLEWOOD, CO – September 3, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced order growth for July and August 2020. Aggregate or
September 9, 2020	8-K	Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
July 28, 2020	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 28, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00
July 28, 2020	EX-99.1	Zynex Announces Second Quarter 2020 Earnings Exhibit 99.1 Zynex Announces Second Quarter 2020 Earnings · Revenue increased 87% year over year to $19.3 million · Orders increased 37% · Net income of $3.0 million; Diluted EPS $0.09 · Adjusted EBITDA increased 69% to $4.8 million ENGLEWOOD, CO – July 28, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical d
July 20, 2020	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 15) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO
July 17, 2020	EX-1.1	Underwriting Agreement dated July 14, 2020, among certain selling stockholders, Piper Sandler & Co., and Zynex, Inc. (incorporated by reference to Exhibit 1.1 of the Company’s Report on Form 8-K filed on July 17, 2020) Exhibit 1.1 Execution Version 2,500,000 Shares1 ZYNEX, INC. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT July 14, 2020 PIPER SANDLER & CO. As Representative of the several Underwriters named in Schedule II hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Zynex, Inc., a Nevada corporation (the “Company”), and
July 17, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 17, 2020	EX-99.1	Zynex, Inc. Prices Public Offering of Common Stock Exhibit 99.1 Zynex, Inc. Prices Public Offering of Common Stock ENGLEWOOD, Colo., July 14, 2020 /PRNewswire/ - Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today the pricing of its previously
July 16, 2020	424B5	Per Share TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-230128 PROSPECTUS SUPPLEMENT (To Prospectus dated March 12, 2019) 1,250,000 Shares ZYNEX, INC. Common Stock $22.00 per share • Zynex, Inc. is offering 1,250,000 shares. • Our common stock is listed on the Nasdaq Capital Market under the symbol “ZYXI.” • The last reported sale price for our common stock on the Nasdaq Capital
July 16, 2020	424B7	Per Share TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(7) Registration No. 333-232367 PROSPECTUS SUPPLEMENT (To Prospectus dated July 3, 2019) 1,250,000 Shares ZYNEX, INC. Common Stock $22.00 per share • The selling stockholders identified in this prospectus supplement are offering an aggregate of 1,250,000 shares of our common stock. We will not receive any of the proceeds from the sale of the shares
July 14, 2020	424B7	SUBJECT TO COMPLETION, DATED JULY 14, 2020 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
July 14, 2020	424B5	SUBJECT TO COMPLETION, DATED JULY 14, 2020 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
July 13, 2020	EX-99.1	Zynex Announces 37% Order Growth and Increases Q2 and Full-Year Revenue Estimates Exhibit 99.1 Zynex Announces 37% Order Growth and Increases Q2 and Full-Year Revenue Estimates ENGLEWOOD, CO – July 9, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased r
July 13, 2020	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
May 21, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.
May 5, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2020 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.S
April 28, 2020	EX-99.1	Zynex Announces 2020 First Quarter Earnings Exhibit 99.1 Zynex Announces 2020 First Quarter Earnings • Revenue increased 66% year over year to $15.2 million • Orders increased 126% • Net income of $2.9 million; Diluted EPS $0.09 • Adjusted EBITDA increased 23% to $3.0 million ENGLEWOOD, CO – April 28, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical
April 28, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, In
April 28, 2020	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.
April 2, 2020	DEFA14A	ZYXI / Zynex, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
April 2, 2020	DEF 14A	definitive proxy statement on Schedule 14A for the Company’s 2020 Annual Meeting of Stockholders filed on April 2, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
March 4, 2020	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 14) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO
February 27, 2020	EX-99.1	Zynex Announces 2019 Fourth Quarter and Full Year Earnings Exhibit 99.1 Zynex Announces 2019 Fourth Quarter and Full Year Earnings · 2019 Full Year o Revenue increased 42% year over year to $45.5 million o Net income $9.5 million; Diluted EPS $0.28 o 2019 Revenue, net income and Adjusted EBITDA are the highest in Company history o Adjusted EBITDA increased 11% to $12.1M · 2019 Fourth Quarter o Revenue increased 52% year over year to $14.2 million o Orders
February 27, 2020	EX-21	Subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF ZYNEX, INC. Name Jurisdiction Zynex Medical, Inc. Colorado Zynex Monitoring Solutions, Inc. Colorado Zynex NeuroDiagnostics, Inc. Colorado Zynex Europe, ApS Denmark Zynex Billing and Consulting, LLC Colorado Pharmazy, Inc Colorado
February 27, 2020	EX-4.2	Exhibit 4.2 to the 2019 Annual Report Exhibit 4.2 . DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Zynex Inc. (“Zynex” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). DESCRIPTION OF COMMON STOCK The authorized capital stock of the Company consists of 110,000,000 shares
February 27, 2020	10-K	Annual Report on Form 10-K for the year ended December 31, 2019 filed on February 27, 2020 (“2019 Annual Report”); UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 ZYNEX, INC. (Exact name o
February 27, 2020	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number
February 25, 2020	EX-99.1	Zynex Receives FDA Clearance for its Blood Volume Monitor Exhibit 99.1 Zynex Receives FDA Clearance for its Blood Volume Monitor ENGLEWOOD, CO – February 25, 2020 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the U.S. Food and Drug Administration (“FD
February 25, 2020	8-K	Regulation FD Disclosure 8-K 1 tm2010867d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incor
January 7, 2020	EX-99.1	Zynex Expands Corporate Headquarters to Accommodate Growth Exhibit 99.1 Zynex Expands Corporate Headquarters to Accommodate Growth Englewood, CO January 7, 2020. Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it has signed an addendum to its corporat
January 7, 2020	EX-10.1	Amendment to Sublease Agreement, effective January 3, 2020, between CSG Systems, Inc. and Zynex, Inc. (incorporated by reference to Exhibit 10.1 of the Company’s Report on Form 8-K filed on January 7, 2020 Exhibit 10.1 FOURTH AMENDMENT TO SUBLEASE This FOURTH AMENDMENT TO SUBLEASE (this “Amendment”) is entered into and made effective as of the 30th day of November, 2019 (“Amendment Date”), by and between CSG SYSTEMS, INC., a Delaware corporation (“Sublandlord”), and ZYNEX, INC., a Nevada corporation (“Subtenant”). RECITALS: A. Maroon Office Partners II, LLC, a Colorado limited liability company, as
January 7, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2020 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I
October 29, 2019	EX-99.1	Zynex Announces 2019 Third Quarter Financial Results Exhibit 99.1 Zynex Announces 2019 Third Quarter Financial Results · Revenue increased 45% year over year to $11.8 million · Orders increased 95% year over year · Net income $2.0 million; Diluted EPS $0.06 · Adjusted EBITDA $2.8M o Thirteenth consecutive quarter of positive net income ENGLEWOOD, CO – October 29, 2019 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializin
October 29, 2019	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2019 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 29, 2019	424B5	The date of this prospectus supplement is October 29, 2019. TABLE OF CONTENTS Prospectus Supplement Filed Pursuant to Rule 424(b)(5) Registration No. 333-230128 Prospectus Supplement (To Prospectus dated March 12, 2019) Up to $50,000,000 Common Stock We have entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Jaffray & Co. (“Piper Jaffray”) as our sales agent, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus
October 29, 2019	EX-1.1	Equity Distribution Agreement, dated October 29, 2019 between Zynex, Inc. and Piper Jaffray & Co. (incorporated by reference to Exhibit 1.1 of the Company’s Current Report on Form 8-K filed on October 29, 2019) Exhibit 1.1 Execution Version ZYNEX, INC. EQUITY DISTRIBUTION AGREEMENT October 29, 2019 PIPER JAFFRAY & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Zynex, Inc., a company organized under the laws of the State of Nevada (the “Company”), proposes to issue and sell from time to time through Pi
October 29, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2019 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (
October 29, 2019	10-Q	ZYXI / Zynex, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex
August 20, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 13) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 8
August 13, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2019 Zynex, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I
July 31, 2019	EX-99.1	Zynex Announces 2019 Second Quarter Earnings Exhibit 99.1 Zynex Announces 2019 Second Quarter Earnings · Revenue increased 36% year over year to $10.3 million · Orders increased 65% year over year · Net income $2.2 million; Diluted EPS $0.06 · Adjusted EBITDA $2.8M · Twelfth consecutive quarter of positive net income ENGLEWOOD, CO – July 31, 2019 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manuf
July 31, 2019	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 31, 2019 Zynex, Inc. (Exact name of Registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) (Commission File Number) (I
July 31, 2019	10-Q	July 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc
July 23, 2019	EX-10.1	Employment Agreement effective July 22, 2019, entered into between Zynex, Inc. and Giuseppe Papandrea Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into effective June 13th, 2019 (the “Effective Date”), by Giuseppe Papandrea (“Executive”) and Zynex Medical (the “Company”). RECITALS A. Company desires to hire Executive as Chief Operating Officer and to compensate Executive for Executive’s services to the Company; and B. Executive wishes to be employed by
July 23, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2019 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R
July 23, 2019	EX-99.1	Zynex Expands Executive Team, Appoints Joseph Papandrea Chief Operating Officer Exhibit 99.1 Zynex Expands Executive Team, Appoints Joseph Papandrea Chief Operating Officer ENGLEWOOD, Colo., (PR Newswire, July 22, 2019) - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it
July 1, 2019	CORRESP	ZYXI / Zynex, Inc. CORRESP - - Zynex, Inc. 9555 Maroon Circle Englewood, CO 80112 July 1, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Zynex, Inc. Registration Statement on Form S-3 File No. 333-232367 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Zynex, Inc. (the “Company”
June 26, 2019	S-3	ZYXI / Zynex, Inc. S-3 - - S-3 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 26, 2019 REGISTRATION NO.
June 11, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 12) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 8
June 10, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 11) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 8
June 6, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 10) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 8
May 24, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 9) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 80
May 17, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 8) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 80
May 13, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 7) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 80
May 7, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 6) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 80
May 3, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2019 Zynex, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) Commission File Number (I.R.S
April 30, 2019	EX-99.1	Zynex Announces 2019 First Quarter Earnings Exhibit 99.1 Zynex Announces 2019 First Quarter Earnings · Revenue increased 34% year over year to $9.2 million · Net income increased 22% to $2.4 million; Diluted EPS $0.07 · Adjusted EBITDA increased 20% to $2.5M o Eleventh consecutive quarter of positive net income ENGLEWOOD, CO – April 30, 2019 – Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufactu
April 30, 2019	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 30, 2019 Zynex, Inc. (Exact name of Registrant as specified in its charter) Nevada 001-38804 90-0275169 (State or other jurisdiction of incorporation) (Commission File Number) (
April 30, 2019	10-Q	April 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, In
April 10, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 4)* INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 8
April 10, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 5) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 80
April 5, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 3) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 80
March 21, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 80
March 19, 2019	SC 13D/A	ZYXI / Zynex, Inc. / Sandgaard Thomas - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) ZYNEX, INC. (Name of Issuer) Common Stock, 0.001 Par Value (Title of Class of Securities) 98986M 103 (CUSIP Number) Thomas Sandgaard 9555 Maroon Circle Englewood, CO 80

ZYXI / Zynex, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)